These companies own 97% of the weight loss drug market -- which could grow tenfold over the next decade -- and are developing ...

Regeneron’s shares have declined nearly 17% following the failure of the company’s Dupixent follow-up itepekimab.

GIP (red),  glucagon (violet) and PYY (green). Each hormone targets its own receptor. The effect of each receptor on the body are indicated using the same color code. The tetra-agonist compound ...

GoodRx says that with the support of a healthcare team, a clear transition plan, and a few cost-saving tools, you can make ...

Novo Nordisk’s stock has tumbled over 50% since its peak around a year ago, and it just ousted its CEO. Former employees say ...

Eli Lilly joins up with Camurus to make long-acting versions of the pharma's obesity and diabetes drugs, joining the industry ...

Based on Caliway's preclinical data, co-administration of CBL-514 with GLP-1 significantly reduced post-discontinuation body weight regain and fat replenishment rate — suggesting that CBL-514 may help ...

GLP-1 drugs like Ozempic are associated with a higher risk of developing wet age-related macular degeneration in people with ...